Prenetics Global (NASDAQ:PRE – Get Free Report) is expected to be releasing its Q3 2026 results before the market opens on Wednesday, November 18th. Analysts expect the company to post earnings of ($0.82) per share and revenue of $63.18 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, November 18, 2026 at 8:30 AM ET.
Prenetics Global (NASDAQ:PRE – Get Free Report) last released its quarterly earnings results on Wednesday, August 19th. The company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.84) by $0.31. Prenetics Global had a negative return on equity of 21.41% and a negative net margin of 47.43%. The company had revenue of $46.49 million during the quarter, compared to analyst estimates of $49.85 million. On average, analysts expect Prenetics Global to post ($2.36) EPS for the current fiscal year and ($1.25) EPS for the next fiscal year.
Prenetics Global Price Performance
Shares of NASDAQ PRE opened at $15.48 on Tuesday. The business’s 50 day moving average is $20.26 and its two-hundred day moving average is $19.55. Prenetics Global has a 1-year low of $11.36 and a 1-year high of $27.24. The stock has a market capitalization of $261.15 million, a P/E ratio of -3.72 and a beta of 0.40.
Analysts Set New Price Targets
Get Our Latest Research Report on Prenetics Global
Insider Activity at Prenetics Global
In related news, CEO Danny Sheng Wu Yeung bought 17,181 shares of the stock in a transaction on Monday, August 24th. The stock was bought at an average price of $21.23 per share, for a total transaction of $364,752.63. Following the completion of the acquisition, the chief executive officer directly owned 112,416 shares in the company, valued at approximately $2,386,591.68. This represents a 18.04% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Brian Rosin purchased 18,000 shares of the stock in a transaction dated Monday, August 24th. The stock was purchased at an average price of $21.19 per share, for a total transaction of $381,420.00. Following the completion of the acquisition, the chief financial officer directly owned 18,000 shares in the company, valued at approximately $381,420. This represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders have purchased 47,781 shares of company stock worth $999,778.
Prenetics Global Company Profile
Prenetics Global Limited is a health sciences company focused on consumer wellness and health-related products. Its portfolio includes IM8, a consumer wellness brand offering nutritional supplements, and CircleDNA, a genetic testing service that provides reports on health, wellness and ancestry. The company has also operated clinical genomic testing services and provided COVID-19 testing during the pandemic. Its business has since shifted toward consumer health and wellness. Prenetics was founded in 2014 and is led by co-founder and Chief Executive Officer Danny Yeung.
Read More
- Five stocks we like better than Prenetics Global
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Prenetics Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prenetics Global and related companies with MarketBeat.com's FREE daily email newsletter.
